Alteración de la densidad del volumen de los componentes testiculares asociada con el cisplatino: ¿pueden los antioxidantes ofrecer protección?

Santana Castro, M. A; Ferreira, U; Glina, S; Santana Castro, A. C; Matheus, W. E; Reis, L. O.
Actas urol. esp ; 34(3): 282-287, mar. 2010. tab
Artículo en Español | IBECS (España) | ID: ibc-81702

Documentos relacionados

  1. Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours.
  2. Outcome of pediatric germ cell tumor with comparison of carboplatin and cisplatin based regimens: A 10-year analysis.
  3. Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective.
  4. Extrinsic apoptosis and senescence involved in growth kinetics of seminoma to cisplatin.
  5. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
  6. Challenges in the management of relapsed germ cell tumors.
  7. Testicular cancer in 2023: Current status and recent progress.
  8. Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial.
  9. 'Burned-Out' primary testicular tumour: Is retroperitoneal lymph node biopsy mandatory prior to initiation of chemotherapy? Report of three cases and a review of the literature.
  10. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments.